Lundbeck tops Q3 expectations following strong sales of ment...

Denmark’s Lundbeck has beat its expectations in third quarter results, following a strong performance from its portfolio of mental health drugs, although its newly-launched migraine drug se

Headache for Zosano as FDA turns down migraine patch

Zosano Pharma has been hit by an FDA rejection of its marketing application for migraine drug Qtrypta, asking for new bioequivalence data.

Salvia raises 26 million euros to finance migraine neurostim...

Salvia BioElectronics has raised 26 million euros ($30 million) in new financing to fund development of a neurostimulation therapy for chronic migraine.

Satsuma pulped as acute migraine drug flunks phase 3 trial

Shares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed to show any improvement over placebo in an acute migraine study.

Lundbeck announces plans to cut a fifth of R&D workforce

Lundbeck has announced plans to cut its research and development team, which could lead to a reduction of up to 160 jobs from an 800-strong department. 

After rejecting Novartis’ Aimovig for migraine, NICE backs T...